{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:33:05Z","timestamp":1781195585279,"version":"3.54.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"30","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["U01AI082196"],"award-info":[{"award-number":["U01AI082196"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R44AI079898"],"award-info":[{"award-number":["R44AI079898"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008143","name":"Oregon National Primate Research Center","doi-asserted-by":"publisher","award":["8P51OD011092-53"],"award-info":[{"award-number":["8P51OD011092-53"]}],"id":[{"id":"10.13039\/100008143","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.vaccine.2018.12.020","type":"journal-article","created":{"date-parts":[[2018,12,31]],"date-time":"2018-12-31T13:55:16Z","timestamp":1546264516000},"page":"4214-4221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine"],"prefix":"10.1016","volume":"37","author":[{"given":"Benjamin K.","family":"Quintel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archana","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danae E.","family":"Poer DeRaad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark K.","family":"Slifka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian J.","family":"Amanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.12.020_b0005","article-title":"Successful Vaccines","author":"Amanna","year":"2018","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2018.12.020_b0010","unstructured":"Food and Drug Administration. Vaccines Licensed for Use in the United States. https:\/\/www.fda.gov\/biologicsbloodvaccines\/vaccines\/approvedproducts\/. [Access Date: Aug 2, 2018]."},{"key":"10.1016\/j.vaccine.2018.12.020_b0015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1203\/PDR.0b013e3180686ce0","article-title":"Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple","volume":"62","author":"Polack","year":"2007","journal-title":"Pediatr Res"},{"key":"10.1016\/j.vaccine.2018.12.020_b0020","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1128\/MMBR.28.2.150-163.1964","article-title":"Kinetics of the inactivation of viruses","volume":"28","author":"Hiatt","year":"1964","journal-title":"Bacteriol Rev"},{"key":"10.1016\/j.vaccine.2018.12.020_b0025","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1128\/AEM.19.2.290-294.1970","article-title":"Effect of formalin, beta-propiolactone, merthiolate, and ultraviolet light upon influenza virus infectivity chicken cell agglutination, hemagglutination, and antigenicity","volume":"19","author":"Goldstein","year":"1970","journal-title":"Appl Microbiol"},{"key":"10.1016\/j.vaccine.2018.12.020_b0030","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1099\/vir.0.018168-0","article-title":"Effect of inactivation method on the cross-protective immunity induced by whole 'killed' influenza A viruses and commercial vaccine preparations","volume":"91","author":"Furuya","year":"2010","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2018.12.020_b0035","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1128\/JCM.02045-09","article-title":"Influenza virus inactivation for studies of antigenicity and phenotypic neuraminidase inhibitor resistance profiling","volume":"48","author":"Jonges","year":"2010","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2018.12.020_b0040","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/nm.2763","article-title":"Development of a new hydrogen peroxide-based vaccine platform","volume":"18","author":"Amanna","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2018.12.020_b0045","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1128\/JVI.02903-12","article-title":"A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice","volume":"87","author":"Pinto","year":"2013","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.12.020_b0050","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.vaccine.2016.11.080","article-title":"Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine","volume":"35","author":"Poore","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.12.020_b0055","doi-asserted-by":"crossref","first-page":"13735","DOI":"10.1128\/JVI.02178-12","article-title":"Characterization of CD8+ T cell function and immunodominance generated with an H2O2-inactivated whole-virus vaccine","volume":"86","author":"Walker","year":"2012","journal-title":"J Virol"},{"issue":"30","key":"10.1016\/j.vaccine.2018.12.020_b0060","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1016\/j.vaccine.2018.12.026","article-title":"An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults","volume":"37","author":"Woods","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.12.020_b0065","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/14760584.2017.1357471","article-title":"Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases","volume":"16","author":"Barrett","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.12.020_b0070","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/0264-410X(94)90259-3","article-title":"Toxin inactivation and antigen stabilization: two different uses of formaldehyde","volume":"12","author":"Rappuoli","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.12.020_b0075","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1084\/jem.20052442","article-title":"Enhancing immunogenicity by limiting susceptibility to lysosomal proteolysis","volume":"203","author":"Delamarre","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.12.020_b0080","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/infdis\/142.5.716","article-title":"Immunogenic correlation between cross-reacting material (CRM197) produced by a mutant of Corynebacterium diphtheriae and diphtheria toxoid","volume":"142","author":"Porro","year":"1980","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.12.020_b0085","first-page":"347","article-title":"Fenton reaction - controversy concerning the chemistry","volume":"16","author":"Barbusi\u0144ski","year":"2009","journal-title":"Ecol Chem Eng"},{"key":"10.1016\/j.vaccine.2018.12.020_b0090","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/0005-2787(72)90509-6","article-title":"The kinetics of degradation of DNA and RNA by H2O2","volume":"272","author":"Massie","year":"1972","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.vaccine.2018.12.020_b0095","doi-asserted-by":"crossref","first-page":"17633","DOI":"10.1074\/jbc.270.29.17633","article-title":"Mapping of copper\/hydrogen peroxide-induced DNA damage at nucleotide resolution in human genomic DNA by ligation-mediated polymerase chain reaction","volume":"270","author":"Rodriguez","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2018.12.020_b0100","series-title":"The Specific Treatment of Virus Diseases","author":"Bauer","year":"1977"},{"key":"10.1016\/j.vaccine.2018.12.020_b0105","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1749-6632.1977.tb21986.x","article-title":"Contact inactivation of RNA and DNA viruses by N-methyl isatin beta-thiosemicarbazone and CuSO4","volume":"284","author":"Fox","year":"1977","journal-title":"Ann N Y Acad Sci."},{"key":"10.1016\/j.vaccine.2018.12.020_b0110","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/0006-2952(76)90153-2","article-title":"Association of nucleic acids with complexes of N-methyl isatin-beta-thiosemicarbazone and copper","volume":"25","author":"Mikelens","year":"1976","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.vaccine.2018.12.020_b0115","doi-asserted-by":"crossref","first-page":"13","DOI":"10.15585\/mmwr.mm6701a3","article-title":"West Nile virus and other Nationally Notifiable Arboviral Diseases - United States, 2016","volume":"67","author":"Burakoff","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2018.12.020_b0120","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1586\/14760584.2014.906309","article-title":"Current trends in West Nile virus vaccine development","volume":"13","author":"Amanna","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2018.12.020_b0125","doi-asserted-by":"crossref","first-page":"163","DOI":"10.4269\/ajtmh.13-0432","article-title":"Lack of evidence of increased West Nile virus disease severity in the United States in 2012","volume":"90","author":"Lindsey","year":"2014","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2018.12.020_b0130","unstructured":"Centers for Disease Control and Prevention. West Nile virus. https:\/\/www.cdc.gov\/westnile\/. [Access Date:Aug 6, 2018]."},{"key":"10.1016\/j.vaccine.2018.12.020_b0135","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1017\/S0950268812001070","article-title":"Estimated cumulative incidence of West Nile virus infection in US adults, 1999\u20132010","volume":"141","author":"Petersen","year":"2013","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2018.12.020_b0140","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.vetmic.2013.03.005","article-title":"Explosive spread of a neuroinvasive lineage 2 West Nile virus in central Europe, 2008\/2009","volume":"165","author":"Bakonyi","year":"2013","journal-title":"Vet Microbiol"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2018.12.020_b0145","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S0168-8278(05)80373-3","article-title":"Development of the formalin-inactivated hepatitis A vaccine, VAQTA from the live attenuated virus strain CR326F","volume":"18","author":"Armstrong","year":"1993","journal-title":"J Hepatol"},{"key":"10.1016\/j.vaccine.2018.12.020_b0150","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00726-003-0011-2","article-title":"Free radical-mediated oxidation of free amino acids and amino acid residues in proteins","volume":"25","author":"Stadtman","year":"2003","journal-title":"Amino Acids"},{"key":"10.1016\/j.vaccine.2018.12.020_b0155","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1038\/emboj.2009.245","article-title":"Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody","volume":"28","author":"Cherrier","year":"2009","journal-title":"EMBO J"},{"key":"10.1016\/j.vaccine.2018.12.020_b0160","doi-asserted-by":"crossref","first-page":"e66507","DOI":"10.1371\/journal.pone.0066507","article-title":"Antibody responses in humans infected with newly emerging strains of West Nile Virus in Europe","volume":"8","author":"Chabierski","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2018.12.020_b0165","doi-asserted-by":"crossref","first-page":"11828","DOI":"10.1128\/JVI.00643-07","article-title":"Induction of epitope-specific neutralizing antibodies against West Nile virus","volume":"81","author":"Oliphant","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2018.12.020_b0170","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1128\/AEM.59.12.4374-4376.1993","article-title":"Virus inactivation by copper or iron ions alone and in the presence of peroxide","volume":"59","author":"Sagripanti","year":"1993","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.vaccine.2018.12.020_b0175","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1021\/es903739f","article-title":"Inactivation of MS2 coliphage in Fenton and Fenton-like systems: role of transition metals, hydrogen peroxide and sunlight","volume":"44","author":"Nieto-Juarez","year":"2010","journal-title":"Environ Sci Technol"},{"key":"10.1016\/j.vaccine.2018.12.020_b0180","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0140-6736(63)90230-7","article-title":"Prophylactic treatment of small pox contacts with N-methylisatin beta-thiosemicarbazone (compound 33t57, Marboran)","volume":"2","author":"Bauer","year":"1963","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2018.12.020_b0185","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1749-6632.1965.tb12545.x","article-title":"Clinical experience with the antiviral drug marboran (1-methylisatin 3-thiosemicarbazone)","volume":"130","author":"Bauer","year":"1965","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.vaccine.2018.12.020_b0195","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0140-6736(66)92529-3","article-title":"Measuring methisazone serum-levels","volume":"288","author":"Gomez","year":"1966","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2018.12.020_b0200","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1099\/0022-1317-28-3-271","article-title":"Arenavirus inactivation on contact with N-substituted isatin beta-thiosemicarbazones and certain cations","volume":"28","author":"Logan","year":"1975","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2018.12.020_b0205","doi-asserted-by":"crossref","first-page":"27402","DOI":"10.1074\/jbc.M504241200","article-title":"Copper-catalyzed protein oxidation and its modulation by carbon dioxide: enhancement of protein radicals in cells","volume":"280","author":"Ramirez","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2018.12.020_b0210","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0167-4838(96)00180-X","article-title":"Hydrogen peroxide-mediated degradation of protein: different oxidation modes of copper- and iron-dependent hydroxyl radicals on the degradation of albumin","volume":"1337","author":"Kocha","year":"1997","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.vaccine.2018.12.020_b0215","doi-asserted-by":"crossref","first-page":"e1005767","DOI":"10.1371\/journal.ppat.1005767","article-title":"Thermostability of well-ordered hiv spikes correlates with the elicitation of autologous tier 2 neutralizing antibodies","volume":"12","author":"Feng","year":"2016","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2018.12.020_b0220","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/0264-410X(95)00076-D","article-title":"Enhancement of protective immune responses to Venezuelan equine encephalitis (VEE) virus with microencapsulated vaccine","volume":"13","author":"Greenway","year":"1995","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2018.12.020_b0225","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1128\/AAC.01178-09","article-title":"Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus","volume":"54","author":"Beigel","year":"2010","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18316918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X18316918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T05:59:58Z","timestamp":1605938398000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X18316918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":44,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0264410X18316918"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.12.020","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.12.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}